

PTC-1449 REPRODUCED

ATTORNEY DOCKET NO.
3769.1000-000APPLICATION NO.
10/501,262SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
IN AN APPLICATIONFIRST NAMED INVENTOR
William Malcolm Charles Rosenberg371(c) DATE:
February 5, 2005EXAMINER
Not yet assignedCONFIRMATION NO.
3832GROUP
1645

August 10, 2005

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS


EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
/AB/	AB	4,415,732	11-15-1983	Caruthers, <i>et al.</i>
/AB/	AC	4,458,066	07-03-1984	Caruthers, <i>et al.</i>
/AB/	AD	4,683,195	07-28-1987	Mullis, <i>et al.</i>
/AB/	AE	4,683,202	07-28-1987	Mullis
/AB/	AF	4,725,677	02-16-1988	Koster, <i>et al.</i>
/AB/	AG	4,973,679	11-27-1990	Caruthers, <i>et al.</i>
/AB/	AH	4,980,460	12-25-1990	Molko, <i>et al.</i>
	AI			
	AJ			
	AK			
	AA2			
	AB2			
	AC2			
	AD2			
	AE2			
	AF2			
	AG2			
	AH2			
	AI2			
	AJ2			
	AK2			
	AA3			
	AB3			
	AC3			
	AD3			

EXAMINER

/Angela Bertagna/

DATE CONSIDERED

08/28/2007

PTO-1449 REPRODUCED 	ATTORNEY DOCKET NO. 3769.1000-000		APPLICATION NO. 10/501,262	
	FIRST NAMED INVENTOR William Malcolm Charles Rosenberg		371(c) DATE: February 5, 2005	
	EXAMINER Not yet assigned	CONFIRMATION NO. 3832	GROUP 1645	

August 10, 2005
(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/AB/	AU ✓	Agrawal, S. and Zamecnik, P.C., "Site Specific Functionalization of Oligonucleotides for Attaching Two Different Reporter Groups," <i>Nucleic Acids Research</i> , 18(18):5419-5423 (1990).
	AV ✓	Beaucage, S.L. and Iyer, R. P., "Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach," <i>Tetrahedron</i> 48(12):2223-2311 (1992).
	AW ✓	Davis, G.L., <i>et al.</i> , "Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C," <i>The New England Journal of Medicine</i> , 339(21):1493-1499 (1998).
	AX ✓	Gut, M., <i>et al.</i> , "One-tube Fluorogenic Reverse Transcription-polymerase Chain Reaction for the Quantitation of Feline Coronaviruses," <i>Journal of Virological Methods</i> , 77:37-46 (1999).
	AY ✓	Holland, P.M., <i>et al.</i> , "Detection of Specific Polymerase Chain Reaction Product by Utilizing the 5'→3' Exonuclease Activity of <i>Thermus aquaticus</i> DNA Polymerase," <i>Proc. Natl. Acad. Sci. USA</i> , 88:7276-7280 (1991).
	AZ ✓	Innis, M.A. and Gelfand, D.H., "Optimization of PCRs" in <i>PCR Protocols: A Guide to Methods and Applications</i> , eds. (NY: Academic Press, Inc.), pp. 3-28 (1990).
	AR2 ✓	Martell, M., <i>et al.</i> , "High-Throughput Real-Time Reverse Transcription-PCR Quantitation of Hepatitis C Virus RNA," <i>Journal of Clinical Microbiology</i> , 37(2):327-332 (1999).
	AS2 ✓	Ozaki, H. and McLaughlin, L.W., "The Estimation of Distances Between Specific Backbone-labeled Sites in DNA Using Fluorescence Resonance Energy Transfer," <i>Nucleic Acids Research</i> , 20(19):5205-5214 (1992).
	AT2 ✓	Poynard, T., <i>et al.</i> , "Randomised Trial of Interferon α 2b Plus Ribavirin for 48 Weeks or for 24 Weeks Versus Interferon α 2b Plus Placebo for 48 Weeks for Treatment of Chronic Infection with Hepatitis C Virus," <i>The Lancet</i> , 352:1426-1432 (1998).
	AU2 ✓	Preudhomme, C., <i>et al.</i> , "Detection of BCR-ABL Transcripts in Chronic Myeloid Leukemia (CML) Using a 'Real Time' Quantitative RT-PCR Assay," <i>Leukemia</i> , 13:957-964 (1999).
/AB/	AV2 ✓	Sambrook, <i>et al.</i> , Molecular Cloning, Second Edition, (Cold Spring Harbor Laboratory, New York), (1989), Chapter 18, pp. 146-152, Chapter 6, pp. 6.1-6.62, Chapter 7, pp. 7.1-7.87, Chapter 14, pp. 14.1-14.35.

EXAMINER /Angela Bertagna/	DATE CONSIDERED 08/28/2007
-------------------------------	-------------------------------

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3769.1000-000	APPLICATION NO. 10/501,262	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION August 10, 2005 (Use several sheets if necessary)		FIRST NAMED INVENTOR William Malcolm Charles Rosenberg		371(c) DATE: February 5, 2005
		EXAMINER Not yet assigned	CONFIRMATION NO. 3832	GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/AB/	AW2 ✓	Simmonds, P., <i>et al.</i> , "Sequence Variability in the 5' Non-coding Region of Hepatitis C Virus: Identification of a New Virus Type and Restrictions on Sequence Diversity," <i>J. Gen. Virol.</i> , 74:661-668 (1993).
/AB/	AX2 ✓	Simmonds, P., <i>et al.</i> , "Classification of Hepatitis C Virus into Six Major Genotypes and a Series of Subtypes of Phylogenetic Analysis of the NS-5 Region," <i>J. Gen. Virol.</i> , 74:2391-2399 (1993).
/AB/	AY2 ✓	Yajima, T., <i>et al.</i> , "Quantitative Reverse Transcription-PCR Assay of the RNA Component of Human Telomerase Using the TaqMan Fluorogenic Detection System," <i>Clinical Chemistry</i> , 44(12):2441-2445 (1998).
/AB/	AZ2✓	Xu, L.-Z., <i>et al.</i> , "Hepatitis C Virus Genotype 4 is Highly Prevalent in Central Africa (Gabon)," <i>J. Gen. Virol.</i> , 75:2393-98 (1994).
	AR3	
	AS3	

EXAMINER /Angela Bertagna/	DATE CONSIDERED 08/28/2007
-------------------------------	-------------------------------

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3769.1000-000		APPLICATION NO. N/A 10/501262	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION July 9, 2004 (Use several sheets if necessary)		FIRST NAMED INVENTOR William Malcolm Charles Rosenberg		FILING DATE	
		EXAMINER Not Assigned		CONFIRMATION NO. N/A	
				GROUP	

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
/AB/	AA	5,851,759	12-22-1998	Weiner
	AB			
	AC			
	AD			
	AE			
	AF			
	AG			
	AH			
	AJ			
	AJ			
	AK			
	AA2			
	AB2			
	AG2			
	AD2			
	AE2			
	AF2			
	AG2			
	AH2			
	AJ2			
	AJ2			
	AK2			
	AA3			
	AB3			
	AC3			

EXAMINER /Angela Bertagna/	DATE CONSIDERED 08/28/2007
-------------------------------	-------------------------------

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3769.1000-000		APPLICATION NO. N/A 10/501262	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION July 9, 2004 (Use several sheets if necessary)		FIRST NAMED INVENTOR William Malcolm Charles Rosenberg		FILING DATE	
		EXAMINER Not Assigned		CONFIRMATION NO. N/A	
				GROUP	

FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
/AB/	AL	WO 01/46469 A1	06-28-2001	Otsuka Pharmaceutical Co., Ltd.		X
	AM					
	AN					
	AO					
	AP					
	AQ					
	AL2					
	AM2					
	AN2					
	AO2					
	AP2					
	AQ2					
	AL3					
	AM3					
	AN3					
	AQ3					
	AP3					
	AQ3					
	AL4					
	AM4					
	AN4					
	AO4					
	AP4					
	AQ4					

EXAMINER /Angela Bertagna/	DATE CONSIDERED 08/28/2007
--------------------------------------	--------------------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION July 9, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3769.1000-000		APPLICATION NO. 100/501262	
	FIRST NAMED INVENTOR William Malcolm Charles Rosenberg		FILING DATE	
	EXAMINER Not Assigned	CONFIRMATION NO. N/A	GROUP	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
/AB/	AR	Bukh, J. <i>et al.</i> , "Sequence analysis of the 5' noncoding region of hepatitis C virus," <i>Proc. Natl. Acad. Sci. USA</i> , 89:4942-4946 (1992).
/AB/	AS	Di Bisceglie, A. M., "Hepatitis C," <i>Lancet</i> , 351:351-355 (1998).
/AB/	AT	Tanaka, Y., <i>et al.</i> , "Selective Binding of Hepatitis C Virus Core Protein to Synthetic Oligonucleotides Corresponding to the 5' Untranslated Region of the Viral Genome," <i>Virol.</i> , 270:229-236 (2000).
	AU	
	AV	
	AW	
	AX	
	AY	
	AZ	
	AR2	
	AS2	
	AT2	
	AU2	
	AV2	
	AW2	
	AX2	

EXAMINER /Angela Bertagna/	DATE CONSIDERED 08/28/2007
----------------------------	----------------------------